Interleukin-33 in Immune Thrombocytopenia: Relation to Disease Severity and Prognosis
Ahmed Said Ali Mohamed;
Abstract
Immune thrombocytopenia (ITP) is the most frequent
childhood autoimmune cytopenia, affecting 2.2–5.3 per
100,000 children aged 18 years or less every year, of which 15-
20% will go on to develop the chronic form. The pathogenesis
of thrombocytopenia in ITP has shifted from the traditional
view of increased platelet destruction mediated by
autoantibodies to more complex mechanisms where both
impaired platelet production and T-cell-mediated effects play a
role. Interleukin-33 (IL-33) is a newly identified cytokine of the
IL-1 family. There is increasing evidence to suggest that IL-33
is a key inflammatory mediator in a complex network of
immune cells and non-immune cells. IL-33 signals via its ST2
receptor and is involved in several autoimmune diseases by
regulating T cell immune responses.
childhood autoimmune cytopenia, affecting 2.2–5.3 per
100,000 children aged 18 years or less every year, of which 15-
20% will go on to develop the chronic form. The pathogenesis
of thrombocytopenia in ITP has shifted from the traditional
view of increased platelet destruction mediated by
autoantibodies to more complex mechanisms where both
impaired platelet production and T-cell-mediated effects play a
role. Interleukin-33 (IL-33) is a newly identified cytokine of the
IL-1 family. There is increasing evidence to suggest that IL-33
is a key inflammatory mediator in a complex network of
immune cells and non-immune cells. IL-33 signals via its ST2
receptor and is involved in several autoimmune diseases by
regulating T cell immune responses.
Other data
| Title | Interleukin-33 in Immune Thrombocytopenia: Relation to Disease Severity and Prognosis | Authors | Ahmed Said Ali Mohamed | Issue Date | 2018 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.